Status:
UNKNOWN
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
Lead Sponsor:
Cairo University
Conditions:
Hyperpigmentation
Melasma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Melasma is a common, acquired, esthetically disfiguring hypermelanosis of the face. Melasma is considered a disappointing challenge when treatment options are addressed. Diverse treatment modalities s...
Eligibility Criteria
Inclusion
- Patients with bilateral nearly symmetric melasma on the face.
Exclusion
- Patients receiving systemic or topical or laser treatment relevant to melasma within three months before enrollment into the study.
- Use of oral or injectable contraceptives or hormone replacement therapy during treatment or 12 months before
- Patients active skin infections and active HSV
- History of hypertrophic scars or keloids.
- Patients with hypercoagulable state or bleeding diatheses
- Pregnant and lactating females.
- History of liver diseases
- Intake of systemic chemotherapy, corticosteroids, antiplatelets or anticoagulants
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04765930
Start Date
October 1 2019
End Date
March 1 2021
Last Update
February 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Cairo University
Cairo, Egypt